Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review

• Үндсэн зохиолчид: Senthil Lingaratnam (Зохиогч), Safeera Yasmeen Hussainy (Зохиогч), Alexandra Murphy (Зохиогч), Cale Perrin (Зохиогч), Melbin Samuvel (Зохиогч), Elahe Mehrvarz (Зохиогч), Chiao Xin Lim (Зохиогч), John Zalcberg (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background Regulatory pathways adopted by the United States Food Drug and Administration (FDA) and Australian Therapeutic Goods Administration (TGA) enable expedited approval of medicines that are thought to offer significant clinical advantage over existing options for severe diseases.Objectives To...